Becton, Dickinson and Company

Becton, Dickinson and Company, commonly branded as BD, is a United States-based medical technology company headquartered in Franklin Lakes, New Jersey. It develops, manufactures and supplies medical devices, diagnostic systems, laboratory instruments, research reagents, medication-management technologies, infection-prevention products and healthcare software. Its customers include hospitals, clinics, laboratories, physicians, pharmaceutical companies, academic institutions, public-health agencies and biomedical researchers. BD traces its origins to 1897, when Maxwell W. Becton and Fairleigh S. Dickinson established a business in New York and began by making clinical thermometers. The company soon expanded into surgical instruments and syringes, building a long-term specialization in products that support the preparation, collection, delivery and analysis of biological materials. It was incorporated in New Jersey in 1906, and its early manufacturing and corporate activities became associated with Rutherford and East Rutherford, New Jersey. Over the twentieth century, BD evolved from a maker of basic clinical supplies into a diversified healthcare-technology enterprise. Syringes, needles, blood-collection systems and safety devices remained central to the business, while the company added microbiology, flow cytometry, molecular diagnostics, specimen-management systems and research tools. The BD Vacutainer family became widely used for blood collection, while BD FACS instruments and reagents became important in cell analysis and immunology research. The company also developed or acquired technologies for laboratory automation, pharmacy operations, medication dispensing, infusion, vascular access, surgery, urology and critical care. BD’s corporate transformation accelerated through large acquisitions. The 2015 purchase of CareFusion expanded the company into medication management, infusion technology, respiratory care, infection prevention and healthcare automation. The 2017 acquisition of C. R. Bard added substantial portfolios in vascular access, oncology, peripheral intervention, urology, surgery and advanced medical devices. These transactions broadened BD’s role from a component and consumables supplier into an integrated medical-technology provider spanning prevention, diagnosis, treatment and care delivery. The company’s principal commercial areas include Medication Delivery Solutions, Medication Management Solutions, Diagnostic Solutions, Biosciences, Interventional products and related medical-device businesses. Its branded offerings include BD syringes and needles, BD Plastipak syringes, BD Vacutainer blood-collection products, BD Alaris infusion systems, BD Pyxis medication-management systems, BD MAX molecular diagnostic platforms, BD Veritor rapid testing systems, BD FACS flow-cytometry platforms and BD Kiestra laboratory automation. Some products acquired through CareFusion and Bard continue to operate as important BD franchises, while others are marketed under legacy brand names within BD’s portfolio. BD positions itself around patient safety, healthcare workflow reliability, infection prevention, diagnostic insight and improved clinical outcomes. Its purpose statement, “advancing the world of health,” reflects an emphasis on technologies that support healthcare professionals rather than consumer-facing wellness products. The company also participates in public-health responses, including infectious-disease testing and laboratory support during the COVID-19 pandemic. BD is a publicly traded company with global operations and sales in more than 190 countries. Its current scale reflects both organic product development and a long history of acquisitions. In fiscal 2025, BD reported worldwide revenue of approximately $21.840 billion, according to its annual report for the year ended September 30, 2025. Tom Polen serves as chairman, chief executive officer and president. The company remains active in product development, regulatory submissions, manufacturing expansion, portfolio management and targeted acquisitions, while also addressing product-safety, quality and regulatory matters associated with a large medical-device portfolio. Becton, Dickinson and Company, commonly known as BD, is a United States-based global medical-technology company. It develops, manufactures, and distributes medical devices, diagnostic systems, laboratory equipment, and related software and services. Although the supplied industry classification identified the business as generic pharmaceuticals, that classification does not match the company’s principal identity: BD is primarily a medical-device, diagnostics, and life-sciences technology group rather than a generic-drug manufacturer. The company was established in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson. Its early business was associated with medical and surgical supplies, and it gradually built a broad portfolio around injection, specimen collection, laboratory, and hospital-use products. Over time, BD became particularly associated with syringes, needles, blood-collection systems, safety-engineered devices, and diagnostic technologies. Its products are used by hospitals, physicians, pharmacies, clinical laboratories, pharmaceutical manufacturers, research institutions, and patients. BD’s business spans several connected areas. Its medication-management activities include infusion pumps, infusion sets, drug-delivery components, prefillable systems, and technologies intended to support safer preparation and administration of medicines. The company also supplies vascular-access and injection products, sharps-safety systems, surgical and urology devices, and products used in oncology and other procedural specialties. In diagnostics and laboratory science, BD provides molecular and microbiology systems, specimen-collection products, flow-cytometry platforms, cell-analysis tools, reagents, and other research technologies. A major phase of expansion came through acquisitions. BD acquired CareFusion in 2015, adding substantial medication-management, infusion, respiratory-care, and patient-monitoring capabilities. In 2017 it completed the acquisition of C. R. Bard, strengthening its presence in vascular, urology, oncology, surgery, and other specialized medical-device markets. These transactions helped transform BD from a company strongly identified with injection and laboratory products into a diversified medical-technology platform. The BD brand is generally positioned around clinical reliability, infection prevention, medication safety, laboratory productivity, and support for healthcare workflows. Its customers often purchase products through institutional procurement channels, making regulatory compliance, clinical evidence, supply continuity, interoperability, and service support important parts of the brand proposition. BD also markets selected products directly or indirectly to consumers, including some diabetes-care and home-use injection products, although the company’s primary commercial base remains professional healthcare and life-sciences users. BD operates internationally, with manufacturing and commercial activities across North America, Latin America, Europe, Asia, and other regions. Reported manufacturing locations include the United States, Canada, Brazil, the Dominican Republic, France, Germany, Hungary, India, Japan, Mexico, and Bosnia and Herzegovina, among others. The company remains headquartered in Franklin Lakes, New Jersey, and is led by Thomas E. Polen, who serves as chairman, president, and chief executive officer. Its current identity is that of a large, diversified healthcare-technology company serving clinical care, diagnostics, research, pharmaceutical production, and medication delivery. BD’s corporate transformation accelerated through large acquisitions. The 2015 purchase of CareFusion expanded the company into medication management, infusion technology, respiratory care, infection prevention and healthcare automation. The 2017 acquisition of C. R. Bard added specialty medical-device capabilities in vascular access, oncology, urology, surgery and interventional care, and led to the creation of the BD Interventional segment. BD continued portfolio development through smaller acquisitions including PureWick, FlowJo, TVA Medical, Parata Systems, MedKeeper, Venclose, Tissuemed, Scanwell Health and Edwards Lifesciences’ Critical Care business. During the COVID-19 pandemic, BD supplied diagnostic and laboratory technologies and introduced SARS-CoV-2 antigen testing on the BD Veritor Plus System. In the 2020s, BD operated as a global medical-technology company organized around medical, diagnostic, bioscience and interventional businesses. Tom Polen became chief executive officer in 2020, was appointed chairman in 2021 and continued as president. The company remains headquartered in Franklin Lakes, New Jersey, is listed on the New York Stock Exchange under the symbol BDX and sells products in more than 190 countries. In 2025, the U.S. Food and Drug Administration published information about BD’s expanded Class I voluntary recall of certain Alaris pump configurations and compatible infusion sets.

BD was founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson. The company’s early development centered on medical glassware and syringes, establishing a manufacturing base in products used directly in clinical care. In 1925, BD introduced the Yale Luer-Lok syringe, whose locking connection helped secure the needle-to-syringe interface and became an enduring industry standard. The company later played a role in the expansion of disposable medical supplies. In 1954, BD mass-produced disposable glass syringes for the mass vaccination campaign involving the Salk polio vaccine. This period reinforced BD’s role as a large-scale supplier to public-health and clinical programs, while also demonstrating the strategic importance of manufacturing consistency and product safety. BD diversified beyond basic injection products during the second half of the twentieth century. In 1974, it licensed fluorescence-activated cell-sorting technology from Stanford University and introduced the FACS-1, described as the first commercial flow cytometer. This move established a major presence in cell analysis and life-science research. The company also built diagnostic and specimen-collection businesses, including the BD Vacutainer line, and expanded into laboratory instruments, reagents, microbiology, and molecular testing. In the twenty-first century, BD increasingly combined consumable products with automation, software, and integrated clinical workflows. The acquisition of KIESTRA Lab Automation in 2012 strengthened its microbiology-laboratory automation capabilities. BD also sold Discovery Labware to Corning in 2012, illustrating the company’s practice of reshaping its portfolio around strategic healthcare and life-science priorities. A major transformation occurred with the acquisition of CareFusion. Announced in 2014 and completed on March 17, 2015, the transaction added infusion pumps, automated medication dispensing, respiratory-care products, and related patient-safety technologies to BD’s existing drug-delivery and vascular-access portfolio. CareFusion became a wholly owned BD subsidiary, and its shares ceased trading. The transaction materially increased BD’s scale in medication management and hospital workflow systems. BD then expanded further through its acquisition of C. R. Bard, announced in 2017 for approximately $24 billion in cash and shares. Bard brought businesses in interventional medicine, oncology, surgery, vascular access, urology, and hernia repair. The combination broadened BD’s geographic reach and product range, particularly in procedure-focused and high-growth medical-device categories. The company’s current model is organized around large healthcare and life-sciences markets. It serves hospitals, laboratories, pharmacies, pharmaceutical companies, researchers, and public-health systems through a mixture of direct sales, distributors, strategic accounts, professional education, scientific meetings, and digital engagement. BD’s brand promise emphasizes advancing health through safer care delivery, more efficient workflows, better diagnostic information, and tools that enable biomedical discovery. Tom Polen serves as chairman, CEO, and president, and BD remains a publicly traded company headquartered in Franklin Lakes, New Jersey.

• 2025

  Fiscal 2025 revenue reached approximately $21.840 billion

  [4]BD 2025 Form 10-Kinvestors.bd.com

  BD reported worldwide fiscal 2025 revenue of approximately $21.840 billion for the year ended September 30, 2025.

• 2024

  Edwards Lifesciences' Critical Care business acquired

  [5]BD recent mergers and acquisitionsbd.com

  BD acquires Edwards Lifesciences' Critical Care business, adding advanced patient-monitoring capabilities.

• 2021

  Tom Polen becomes chairman

  [2]Tom Polen leadership profilebd.com

  Polen is appointed chairman while continuing as chief executive officer and president.

• 2021

  Thomas E. Polen becomes chairman and CEO

  [14]BD executive profileglobaldata.com

  Thomas E. Polen assumed the roles of chairman, president, and chief executive officer.

• 2020

  Tom Polen becomes chief executive officer

  [2]Tom Polen leadership profilebd.com

  Tom Polen becomes BD chief executive officer after serving as president and chief operating officer.

• 2020

  BD Veritor SARS-CoV-2 testing launched

  [11]BD sustainability report and COVID-19 testing responsebd.com

  BD adds rapid SARS-CoV-2 antigen testing to the BD Veritor Plus System during the COVID-19 pandemic.

• 2017

  Agreement to acquire C. R. Bard

  [8]BD announces C. R. Bard acquisitioninvestors.bd.com

  BD announces a proposed acquisition of Bard valued at approximately $24 billion, creating a broader interventional and specialty-device portfolio. BD completes the Bard transaction and establishes a larger global medical-technology platform with expanded vascular, surgical, urological and interventional capabilities.

• 2017

  C. R. Bard acquisition completed

  [9]BD completes C. R. Bard acquisitioninvestors.bd.com

  BD completes the Bard transaction and establishes a larger global medical-technology platform with expanded vascular, surgical, urological and interventional capabilities. BD announced an approximately $24 billion cash-and-stock acquisition of C. R. Bard, adding major oncology, surgery, vascular, and urology businesses.

• 2015

  CareFusion acquisition completed

  [6]BD completes CareFusion acquisitioninvestors.bd.com

  CareFusion becomes a wholly owned BD subsidiary, adding infusion, medication-management, respiratory-care and infection-prevention businesses.

• 2014

  Agreement to acquire CareFusion

  [7]BD announces CareFusion acquisitioninvestors.bd.com

  BD announces a transaction valued at approximately $12.2 billion to acquire CareFusion and expand into medication management and patient safety.

• 2012

  Kiestra laboratory automation acquisition

  [5]BD recent mergers and acquisitionsbd.com

  BD acquires Kiestra Lab Automation, strengthening its laboratory workflow and microbiology automation capabilities.

• 1957

  BD Plastipak syringe introduced

  [12]BD Plastipak historical timelinego.bd.com

  BD develops an early fully sterile single-use disposable plastic syringe, establishing a major long-term product platform.

• 1950

  Expansion into modern disposable medical products

  [12]BD Plastipak historical timelinego.bd.com

  BD expands its use of plastics and sterile manufacturing, contributing to the development of single-use medical products.

• 1906

  New Jersey incorporation and early plant

  [17]New Jersey incorporation and early plantinvestors.bd.com

  The company is incorporated under New Jersey law and develops an early plant and headquarters in East Rutherford.

• 1897

  Becton, Dickinson and Company is founded

  [3]BD history and originsjobs.bd.com

  Maxwell W. Becton and Fairleigh S. Dickinson establish the business in New York and begin with clinical thermometers.

A clinically focused, high-scale medical technology provider positioned around patient safety, reliable healthcare workflows, diagnostic insight, medication management, infection prevention, biomedical research and improved clinical outcomes. A global healthcare-technology partner focused on safer medication delivery, injection and vascular access, infection prevention, diagnostics, laboratory science, and specialized procedural care.

• Injection and medication delivery · 1897

  BD Syringes and Needles

  BD's syringe and needle portfolio includes general-purpose syringes, safety-engineered devices, insulin-related products and specialty injection components. The portfolio is used in hospitals, clinics, pharmacies, laboratories and home-care settings. Its products are designed around dose accuracy, sterility, compatibility with medication-delivery workflows and reduction of needlestick exposure.

• Disposable plastic syringes · 1957

  BD Plastipak

  BD Plastipak is a major disposable syringe family associated with BD's long history of plastic medical-device manufacturing. The platform emphasizes sterile, single-use design and is available in multiple sizes and configurations for medication administration, laboratory work and other clinical procedures. BD Plastipak is a syringe family used for medical injection and medication administration. The products are supplied in formats for healthcare, pharmaceutical, and other professional applications and form part of BD’s longstanding injection-technology business.

• Blood collection and specimen management

  BD Vacutainer

  BD Vacutainer includes evacuated blood-collection tubes, specimen-collection accessories and related systems used to collect, transport and prepare blood samples. The product family supports standardized specimen handling in hospitals, outpatient laboratories, physician offices and public-health testing environments. BD Vacutainer is a blood-collection product family used by healthcare professionals and laboratories. It includes collection tubes and related devices designed to standardize specimen collection, transport, and preparation for diagnostic testing.

• Infusion and medication delivery

  BD Alaris

  BD Alaris is a family of infusion pumps, pump modules, infusion sets and related technologies acquired through CareFusion. It is designed to support controlled delivery of fluids and medications in acute-care settings. The platform is integrated into hospital medication-administration workflows and is subject to extensive safety, quality and regulatory requirements. BD Alaris is a family of infusion and medication-management technologies used in clinical settings to help deliver fluids, medicines, and nutrition. The offering is associated with infusion pumps, administration sets, and related systems intended to support hospital workflows and medication-safety practices.

• Medication management and pharmacy automation

  BD Pyxis

  BD Pyxis is a family of automated medication-dispensing, inventory-management and workflow systems used by hospitals and pharmacies. The platform is intended to improve medication availability, accountability, storage and administration while connecting pharmacy operations with nursing workflows and electronic systems.

• Molecular diagnostics

  BD MAX

  BD MAX is an automated molecular-diagnostics platform used for nucleic-acid testing. It supports a range of assays for infectious disease and other clinical applications, combining sample preparation, amplification and detection within a laboratory workflow intended to improve consistency and throughput.

• Rapid point-of-care diagnostics · 2020

  BD Veritor

  BD Veritor is a point-of-care diagnostic platform supporting rapid antigen testing. During the COVID-19 pandemic, BD used the Veritor Plus System for SARS-CoV-2 testing. The platform is designed for near-patient use and provides digitally interpreted results for selected assays.

• Flow cytometry

  BD FACS

  BD FACS instruments, reagents and software support flow cytometry and cell-analysis applications. Researchers and clinical laboratories use the portfolio for immunophenotyping, cell biology, oncology research, hematology and other applications requiring multiparameter analysis of individual cells.

• Laboratory automation · 2012

  BD Kiestra

  BD Kiestra provides automation and workflow technologies for clinical microbiology laboratories. The systems help standardize specimen processing, incubation, imaging, plate handling and laboratory information flow, with the aim of improving productivity, traceability and turnaround time.

• Skin antisepsis and infection prevention

  BD ChloraPrep

  BD ChloraPrep is a skin-antisepsis product family used before invasive procedures and device placement. It is part of BD's infection-prevention portfolio and is positioned around reducing microbial contamination at the procedural site.

• Female external urine management · 2017

  BD PureWick

  BD PureWick is an external urine-management system designed for women in healthcare settings. The product was acquired by BD and is intended to support non-invasive urine collection and help reduce the use of indwelling urinary catheters in appropriate patients.

• Molecular diagnostics

  BD COR System

  The BD COR System is a laboratory automation and molecular-diagnostics platform designed to support testing workflows. BD’s communications present it as a system intended to integrate instruments, assays, and workflow processes for clinical laboratories.

• Urology

  BD Aptra Ureteroscope

  The BD Aptra Ureteroscope is a urology device used in endoscopic procedures involving the urinary tract. BD promoted the product through physician-focused educational and testimonial video content in the United States.

• Flow cytometry and cell analysis

  BD FACSLyric

  BD FACSLyric is part of BD’s flow-cytometry portfolio. Such systems enable laboratories to analyze cells and other particles using fluorescence and related measurements, supporting clinical testing, biomedical research, and immunology applications.

• 2025

  BD Alaris pump Class I voluntary recall expansion

  BD expanded a voluntary Class I recall concerning certain BD Alaris Pump Module model 8100 configurations used with a subset of compatible infusion sets. The FDA-described issue involved possible pump-performance variation under certain use cases compared with the performance described in the user manual, with potential implications for infusion delivery. The matter is treated as a product-safety and regulatory event rather than a finding of intentional misconduct.

  Source

Read more

• 2023BD COR System Value Proposition

  United States

  An internet video campaign communicated the clinical and workflow value of the BD COR System to a professional healthcare audience.

  Source
• 2023BD Aptra Ureteroscope physician testimonial

  United States

  BD used a physician-led video featuring Dr. Stoller to discuss the BD Aptra Ureteroscope and its relevance to urological practice.

  Source
• 2020BD Veritor COVID-19 testing response

  United States · Global

  BD promoted and supplied rapid SARS-CoV-2 antigen testing through the BD Veritor Plus System as part of the healthcare response to the COVID-19 pandemic. The initiative connected BD's diagnostic platform with near-patient testing needs in hospitals, clinics, schools, workplaces and public-health programs.

  Outcome. The Veritor platform became one of BD's visible pandemic-response products, although market demand and use depended on regulatory authorizations and local testing policies.

  Source
• 2020Advancing the world of health

  Global

  BD used its corporate purpose, “advancing the world of health,” to organize communications around patient safety, healthcare access, medical discovery and technologies supporting clinicians and researchers.

  Outcome. The purpose statement became a central element of BD's corporate positioning and public communications.

  Source

• 2025

  Expand BD Alaris corrective actions and recallOther

  Background

  Regulatory and customer communications identified possible differences between certain Alaris pump performance and the descriptions in the user manual under specified use conditions.

  Action taken

  BD expanded a Class I voluntary recall and communicated corrective information concerning the affected pump module and compatible infusion sets.

  Aftermath

  The FDA published the updated recall information, and BD continued customer and regulatory remediation activities.

  Source

• 2024

  Acquire Edwards Lifesciences' Critical Care businessM&A

  Background

  BD pursued expansion in advanced patient monitoring and critical-care technologies.

  Action taken

  BD acquired Edwards Lifesciences' Critical Care business.

  Aftermath

  The acquired business contributed to BD's patient-monitoring and critical-care portfolio, including products reflected in later revenue reporting.

  Source

• 2020

  Launch SARS-CoV-2 antigen testing on BD Veritor PlusProduct launch

  Background

  The COVID-19 pandemic created urgent demand for rapid diagnostic tests that could be used outside centralized laboratories.

  Action taken

  BD added SARS-CoV-2 antigen testing to the Veritor Plus point-of-care platform.

  Aftermath

  The product became part of BD's pandemic-response portfolio and supported rapid testing programs subject to applicable regulatory authorizations.

  Source

• 2017

  Acquire C. R. BardM&A

  Background

  BD sought to add specialty medical-device capabilities in vascular access, oncology, urology, surgery and interventional care while expanding international scale.

  Action taken

  BD agreed to acquire C. R. Bard in a cash-and-stock transaction valued at approximately $24 billion.

  Aftermath

  The transaction closed in December 2017 and led to the creation of a larger interventional and specialty-device platform within BD. Bard became part of BD, broadening the company’s specialty-device portfolio and geographic reach.

  Announced transaction value. $24 billion announced consideration (April 23, 2017 announcement)

  Source

• 2017

  Create the BD Interventional segmentStrategy

  Background

  The Bard acquisition added a large collection of vascular, urological, surgical and oncology businesses requiring distinct commercial and operating management.

  Action taken

  BD planned a dedicated Interventional segment for the Bard businesses and related BD activities.

  Aftermath

  Interventional became a major component of BD's post-Bard operating structure and portfolio identity.

  Source

• 2015

  Integrate CareFusion into BD's medication-management strategyStrategy

  Background

  CareFusion provided products spanning medication preparation, dispensing, administration, monitoring, infection prevention and respiratory care.

  Action taken

  BD incorporated CareFusion businesses and brands into a broader strategy focused on medication management, patient safety and healthcare workflow automation.

  Aftermath

  BD gained major hospital-automation brands including Alaris and Pyxis and increased its presence in clinical informatics and medication delivery.

  Source

• 2015

  Acquire CareFusionM&A

  Background

  BD sought to broaden its medical-technology portfolio and increase its presence in medication management and hospital care.

  Action taken

  BD completed the acquisition of CareFusion in a transaction valued at approximately $12 billion.

  Aftermath

  The transaction added infusion, respiratory-care, and medication-management businesses to BD’s operations.

• 2014

  Acquire CareFusionM&A

  Background

  BD sought to expand from traditional medical supplies and devices into medication management, patient safety, infusion, respiratory care and healthcare automation.

  Action taken

  BD agreed to acquire CareFusion in a cash-and-stock transaction valued at approximately $12.2 billion.

  Aftermath

  The acquisition closed in March 2015 and added CareFusion's medication-management, infusion and patient-safety businesses to BD.

  Announced transaction value. $12.2 billion announced consideration (October 5, 2014 announcement)

  Source

• 2026

  BD announced a new general counsel[19]BD announced a new general counselnews.bd.com

  Leadership change

  BD announced the appointment of Lanesha Minnix as general counsel and said she would report to Tom Polen and join the executive leadership team.

• 2025

  BD reported fiscal 2025 worldwide revenue of approximately $21.840 billion[4]BD 2025 Form 10-Kinvestors.bd.com

  Other

  BD's annual report for the fiscal year ended September 30, 2025 reported worldwide revenue of approximately $21.840 billion, with United States revenue of approximately $12.790 billion and international revenue of approximately $9.049 billion.

• 2025

  BD expanded the voluntary recall of certain BD Alaris pump infusion sets[10]FDA notice on BD Alaris recallfda.gov

  Recall · Regulation

  BD expanded a Class I voluntary recall concerning the Alaris Pump Module model 8100 when used with a subset of compatible infusion sets because performance under certain use conditions could differ from the user manual and affect infusion delivery.

• 2023

  BD promotes the clinical value of the COR System[15]BD media and campaign listingsglobaldata.com

  Campaign

  BD used an internet video to communicate the value proposition of its COR System, a platform associated with interventional and procedural care.

• 2023

  BD presents the BD Aptra ureteroscope through physician-led video[15]BD media and campaign listingsglobaldata.com

  Product launch · Campaign

  A physician testimonial video highlighted the BD Aptra ureteroscope for a United States clinical audience.

• 2020

  BD launched SARS-CoV-2 testing on the BD Veritor Plus System[11]BD sustainability report and COVID-19 testing responsebd.com

  Product launch · Campaign

  BD introduced a rapid point-of-care antigen testing capability on the Veritor Plus System during the COVID-19 pandemic, with results designed to be produced in approximately 15 minutes.

• 2017

  BD completed its acquisition of C. R. Bard[9]BD completes C. R. Bard acquisitioninvestors.bd.com

  M&A

  BD completed the acquisition of C. R. Bard, creating a larger medical-technology company with expanded capabilities in vascular access, surgery, oncology, urology and interventional care.

• 2017

  BD agrees to acquire C. R. Bard for approximately $24 billion[16]CNBC report on BD’s acquisition of C. R. Bardcnbc.com

  M&A

  BD announced a cash-and-stock transaction for C. R. Bard. The combination expanded BD’s presence in oncology, surgery, vascular care, and urology, with Bard shareholders expected to own about 15% of the combined company.

• 2015

  BD completed its acquisition of CareFusion[6]BD completes CareFusion acquisitioninvestors.bd.com

  M&A · strategy

  CareFusion became a wholly owned subsidiary of BD, expanding BD's presence in medication management, infusion, patient safety, respiratory care and healthcare automation.

1. 1BD Our Companybd.com
2. 2Tom Polen leadership profilebd.com
3. 3BD history and originsjobs.bd.com
4. 4BD 2025 Form 10-Kinvestors.bd.com
5. 5BD recent mergers and acquisitionsbd.com
6. 6BD completes CareFusion acquisitioninvestors.bd.com
7. 7BD announces CareFusion acquisitioninvestors.bd.com
8. 8BD announces C. R. Bard acquisitioninvestors.bd.com
9. 9BD completes C. R. Bard acquisitioninvestors.bd.com
10. 10FDA notice on BD Alaris recallfda.gov
11. 11BD sustainability report and COVID-19 testing responsebd.com
12. 12BD Plastipak historical timelinego.bd.com
13. 13BD company overview and media profileglobaldata.com
14. 14BD executive profileglobaldata.com
15. 15BD media and campaign listingsglobaldata.com
16. 16CNBC report on BD’s acquisition of C. R. Bardcnbc.com
17. 17New Jersey incorporation and early plantinvestors.bd.com
18. 18Create the BD Interventional segmentnews.bd.com
19. 19BD announced a new general counselnews.bd.com
20. 20Leeds based medical device manufacturer Tissuemed is acquired by US-based Becton Dickinsonyorkshirepost.co.uk